Company profile: Diality
1.1 - Company Overview
Company description
- Provider of the Moda-flx Hemodialysis System, a portable hemodialysis machine for home use that enables patients with kidney disease to self-treat; a medical device company developing solutions that improve lives impacted by kidney disease.
Products and services
- Kidney Disease Life-Improvement Medical Devices: Diality develops medical-grade products improving lives impacted by kidney disease, engineering devices focused on kidney health and patient benefit
- Moda-flx Hemodialysis System: A portable, home-care-grade hemodialysis machine enabling kidney disease patients to self-treat at home with mobility and independent operation
- Strategic Sourcing Manager Role: An operational-scale role optimizing procurement processes, driving cost savings, and maintaining supplier relationships supporting Diality’s operations
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Diality
NxStage
HQ: United States
Website
- Description: Provider of medical devices and patient support for kidney failure, fluid overload, and related blood treatments and procedures, including the NxStage System One portable home hemodialysis machine, Liberty Select peritoneal dialysis cycler, Stay•safe PIN connectors, and services such as a dialysis center directory, educational webinars, and customer service.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NxStage company profile →
Iviva Medical
HQ: United States
Website
- Description: Provider of bioartificial kidney solutions for end-stage kidney disease, including fully implantable bioartificial kidneys; proprietary 3D-printed scaffold construction for human-scale solute-exchange grafts; Thin Film Interposition scaffolding; biologic blood purification with a cellular membrane-based device; and autologous renal grafts from patient-derived cells potentially eliminating the need for immunosuppression.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Iviva Medical company profile →
LTX
HQ: United States
Website
- Description: Provider of pharmaceutical therapies for critically ill patients, developing an anticoagulant for ICU patients with kidney failure undergoing continuous renal replacement therapy (CRRT), a 24/7 dialysis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full LTX company profile →
Renibus Therapeutics
HQ: United States
Website
- Description: Provider of therapeutics to prevent and treat kidney disease, with RBT-1 (single-dose IV before elective cardiac surgery to reduce post-operative complications; Phase 3), Veverimer (oral hydrochloric acid binder for orphan diseases), RBT-3 (iron nanoparticle to restore iron and improve blood product use in cardiac surgery and ER), RBT-9 (anti-inflammatory/antioxidant for COVID-19), and RBT-2 (oral antioxidant/antifibrotic to delay CKD).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Renibus Therapeutics company profile →
Purespring Therapeutics
HQ: United Kingdom
Website
- Description: Provider of AAV gene therapy programs for kidney diseases, targeting podocytes to address monogenic and more common forms, and the FunSel in‑vivo AAV-based screening platform that utilizes libraries of biological factors to identify new kidney gene therapy candidates.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Purespring Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Diality
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Diality
2.2 - Growth funds investing in similar companies to Diality
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Diality
4.2 - Public trading comparable groups for Diality
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →